L3VLUP
ProSign in

TGTX in the 13F filings

TG Therapeutics Inc · CUSIP 88322Q108

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 4 listed it in both
Shares listed
5,571,062
combined, among listed positions
Reported value
$47m
combined, at the quarter end

Managers listing TGTX in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Two Sigma Investments LP2,341,354$20m0.05%Added+508,97214 Nov 2023 (the filing on sec.gov)
Voloridge Investment Management LLC1,612,534$13m0.07%Added+958,95414 Nov 2023 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC1,367,400$11m0.09%Added+850,50714 Nov 2023 (the filing on sec.gov)
Woodline Partners LP152,139$1.3munder 0.1%Added+10,63914 Nov 2023 (the filing on sec.gov)
Moore Capital Management LP97,635$816kunder 0.1%Newnew14 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
6 in Q3 2024 to 8 in Q2 2026

Tracked managers listing it, at least.

02468201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TGTX by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20182$9.0mn.a.n.a.
Q1 20192$50mn.a.n.a.
Q2 20192$52mn.a.n.a.
Q3 20191$42mn.a.n.a.
Q1 20201$162kn.a.n.a.
Q2 20204$47mn.a.n.a.
Q3 20203$416mn.a.n.a.
Q4 20207$1.3bnn.a.n.a.
Q1 20216$1.4bnn.a.n.a.
Q2 20216$1.2bnn.a.n.a.
Q3 20214$893mn.a.n.a.
Q4 20212$194mn.a.n.a.
Q1 20222$74mn.a.n.a.
Q2 20222$29mn.a.n.a.
Q3 20222$51mn.a.n.a.
Q4 20225$108mn.a.n.a.
Q1 20233$55mn.a.n.a.
Q2 20237$154mn.a.n.a.
Q3 20235$47mn.a.n.a.
Q4 20232$36m12
Q1 20243$37m21
Q2 20246$109m60
Q3 20246$94m43
Q4 20243$2.7m03
Q1 20255$57m31
Q2 20254$49m31
Q3 20256$102m51
Q4 20256$83m238
Q1 20265$88m1417
Q2 20268$445m2110

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TGTX and LLY →TGTX and JNJ →TGTX and VRTX →Choose a stock to compare with TGTX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TGTX, latest filings →Back to the 13F Explorer →